Table 2.
Survey Responses
| Item | n (%) |
|---|---|
| Country | 19 Missing |
| USA | 317 (64) |
| Other | 182 (36) |
| Q1. Age | 78 Missing |
| 20–30 | 6 (1) |
| 31–40 | 74 (17) |
| 41–50 | 132 (30) |
| 51–60 | 147 (33) |
| 61+ | 81 (18) |
| Q2. Level of training | 6 Missing |
| Attending | 209 (41) |
| Fellow | 61 (12) |
| Senior Attending (20+ years) | 242 (47) |
| Q3. Use intracorporeal power morcellator | 5 Missing |
| No | 313 (61) |
| Yes | 200 (39) |
| Q4. Reason for not using power morcellator | 1 Missing |
| Not comfortable | 61 (20) |
| Hospital does not keep in stock | 53 (17) |
| Hospital banned morcellator | 149 (48) |
| NA | 49 (16) |
| Q5. Hospital have policy about morcellation | 6 Missing |
| DK | 31 (6) |
| No | 207 (40) |
| Yes | 274 (54) |
| Q6. Heard about press concerning dissemination of occult uterine malignancy after morcellation | 4 Missing |
| No | 19 (4) |
| Yes | 495 (96) |
| Q7. Will risk of disseminated disease make you stop using morcellator | 6 Missing |
| No | 339 (66) |
| Yes | 173 (34) |
| Q8. Does morcellation of occult malignancy affect survival | 7 Missing |
| No | 204 (40) |
| Yes | 307 (60) |
| Q9. Can morcellation disseminate benign pathology, including endometriosis and fibroids | 4 Missing |
| No | 160 (31) |
| Yes | 354 (69) |
| Q10. Personally seen uterine sarcoma diagnosed not suspected pre-op | 4 Missing |
| No | 268 (52) |
| Yes | 246 (48) |
| Q11. What percent of your cases are performed open, laparoscopic, robotic, or MIS with mini-incision for tissue extraction? | |
| Open | 41 Missing |
| <10% | 286 (60) |
| 10–25% | 75 (16) |
| 25–49% | 41 (9) |
| 50% | 31 (6) |
| 51–75% | 17 (3) |
| 75–90% | 14 (3) |
| >90% | 13 (3) |
| Laparoscopic | 30 Missing |
| <10% | 45 (9) |
| 10–25% | 65 (13) |
| 25–49% | 72 (15) |
| 50% | 53 (11) |
| 51–75% | 67 (14) |
| 75–90% | 89 (18) |
| >90% | 97 (20) |
| Robotic | 141 Missing |
| <10% | 195 (51) |
| 10–25% | 33 (9) |
| 25–49% | 44 (12) |
| 50% | 12 (3) |
| 51–75% | 34 (9) |
| 75–90% | 30 (8) |
| >90% | 29 (8) |